Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

Eukaryotic cells can synthesize the non‐essential amino acid arginine from aspartate and citrulline using the enzyme argininosuccinate synthetase (ASS). It has been observed that ASS is underexpressed in various types of cancers ASS, for which arginine become auxotrophic. Arginine deiminase (ADI) is a prokaryotic enzyme that metabolizes arginine to citrulline and has been found to inhibit melanoma and hepatoma cancer cells deficient of ASS. We tested the hypothesis that pancreatic cancers have low ASS expression and therefore arginine deprivation by ADI will inhibit cell growth. ASS expression was examined in 47 malignant and 20 non‐neoplastic pancreatic tissues as well as a panel of human pancreatic cancer cell lines. Arginine deprivation was achieved by treatment with a recombinant form of ADI formulated with polyethylene glycol (PEG‐ADI). Effects on caspase activation, cell growth and cell death were examined. Furthermore, the effect of PEG‐ADI on the in vivo growth of pancreatic xenografts was examined. Eighty‐seven percent of the tumors lacked ASS expression; 5 of 7 cell lines similarly lacked ASS expression. PEG‐ADI specifically inhibited growth of those cell lines lacking ASS. PEG‐ADI treatment induced caspase activation and induction of apoptosis. PEG‐ADI was well tolerated in mice despite complete elimination of plasma arginine; tumor growth was inhibited by ∼50%. Reduced expression of ASS occurs in pancreatic cancer and predicts sensitivity to arginine deprivation achieved by PEG‐ADI treatment. Therefore, these findings suggest that arginine deprivation by ADI could provide a beneficial strategy for the treatment of pancreatic cancer, a malignancy in which new therapy is desperately needed. © 2008 Wiley‐Liss, Inc.

[1]  M. J. Abedin,et al.  Autophagy delays apoptotic death in breast cancer cells following DNA damage , 2007, Cell Death and Differentiation.

[2]  T. Yeatman,et al.  Depletion of dietary arginine inhibits growth of metastatic tumor. , 1991, Archives of surgery.

[3]  W. Souba,et al.  Arginine Metabolism: Enzymology, Nutrition, and Clinical Significance , 2004 .

[4]  Ju-Han Lee,et al.  Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase , 2007, International journal of cancer.

[5]  F. Zölzer,et al.  Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. , 1999, Biochemical and biophysical research communications.

[6]  C. Volteau,et al.  Manipulation of citrulline availability in humans. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[7]  Y. Yu,et al.  Coinduction of Nitric Oxide Synthase, Argininosuccinate Synthetase, and Argininosuccinate Lyase in Lipopolysaccharide-treated Rats , 1996, The Journal of Biological Chemistry.

[8]  J. Hahn.  Guide to protein purification. , 1990, Methods in enzymology.

[9]  S. Emr,et al.  Autophagy as a regulated pathway of cellular degradation. , 2000, Science.

[10]  C. Moinard,et al.  Almost all about citrulline in mammals , 2005, Amino Acids.

[11]  S. Curley,et al.  Regression of hepatocellular cancer in a patient treated with arginine deiminase. , 2003, Hepato-gastroenterology.

[12]  D. Fennell,et al.  In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion , 2006, Clinical Cancer Research.

[13]  A. Lavoinne,et al.  IL-1β stimulates argininosuccinate synthetase gene expression through NF-κB in Caco-2 cells , 2005 .

[14]  Min Young Kim,et al.  Characterization of mycoplasma arginine deiminase expressed in E. coli and its inhibitory regulation of nitric oxide synthesis. , 2002, Molecules and cells.

[15]  R. Wolfe,et al.  Arginine Metabolism: Enzymology, Nutrition, and Clinical Significance , 2004 .

[16]  C V Byus,et al.  Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse. , 1991, Cancer research.

[17]  A. Kimchi,et al.  Autophagy as a cell death and tumor suppressor mechanism , 2004, Oncogene.

[18]  W. Rose,et al.  The amino acid requirements of man. V. The rôle of lysine, arginine, and tryptophan. , 1954, The Journal of biological chemistry.

[19]  A. Lavoinne,et al.  Glutamine increases argininosuccinate synthetase mRNA levels in rat hepatocytes. The involvement of cell swelling. , 1996, European journal of biochemistry.

[20]  S. Freytag,et al.  Synergistic activation of a human promoter in vivo by transcription factor Sp1 , 1991, Molecular and cellular biology.

[21]  W. O'Brien.  Isolation and characterization of argininosuccinate synthetase from human liver. , 1979, Biochemistry.

[22]  R. Bold,et al.  Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomib , 2005, Cancer Chemotherapy and Pharmacology.

[23]  S. Morris.  Enzymes of arginine metabolism. , 2004, The Journal of nutrition.

[24]  Y. Leung,et al.  Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. , 2007, Cancer research.

[25]  D. Wheatley.  Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. , 2005, Seminars in cancer biology.

[26]  T. Ikejima,et al.  Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. , 2007, Biological & pharmaceutical bulletin.

[27]  A. Lavoinne,et al.  Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. , 2003, European journal of biochemistry.

[28]  Daniel J. Klionsky,et al.  Autophagy: from phenomenology to molecular understanding in less than a decade , 2007, Nature Reviews Molecular Cell Biology.

[29]  J. Bomalaski,et al.  Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. , 2002, Cancer research.

[30]  Li-Jiuan Shen,et al.  Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. , 2003, Cancer letters.

[31]  Y. Tsujimoto,et al.  Another way to die: autophagic programmed cell death , 2005, Cell Death and Differentiation.

[32]  Y. Hattori,et al.  Argininosuccinate synthetase mRNA and activity are induced by immunostimulants in vascular smooth muscle. Role in the regeneration or arginine for nitric oxide synthesis. , 1994, The Journal of biological chemistry.

[33]  A. Lavoinne,et al.  Glutamine Stimulates Argininosuccinate Synthetase Gene Expression through Cytosolic O-Glycosylation of Sp1 in Caco-2 Cells* , 2003, Journal of Biological Chemistry.

[34]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Bomalaski,et al.  Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[36]  E. Gilroy.  The influence of arginine upon the growth rate of a transplantable tumour in the mouse. , 1930, The Biochemical journal.

[37]  A. Beaudet,et al.  Metabolite regulation of argininosuccinate synthetase in cultured human cells. , 1988, The Journal of biological chemistry.

[38]  Li-Jiuan Shen,et al.  Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. , 2006, Cancer letters.

[39]  J. Boos,et al.  The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined? , 2004, British journal of haematology.

[40]  Nicolle H. Packer,et al.  Amino acid analysis protocols , 2000 .

[41]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Schimke.  ENZYMES OF ARGININE METABOLISM IN MAMMALIAN CELL CULTURE. I. REPRESSION OF ARGININOSUCCINATE SYNTHETASE AND ARGININOSUCCINASE. , 1964, The Journal of biological chemistry.

[43]  D N Wheatley,et al.  Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilisation of citrulline by malignant cells , 2003, British Journal of Cancer.

[44]  J. Bomalaski,et al.  Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[45]  C. Thompson,et al.  The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment , 2007, Clinical Cancer Research.